Determinants of expert-advised antibiotic indication in pediatric emergency department, data from a cross-sectional prevalence survey
Abstract
Objective Antibiotic resistance and inappropriate antibiotic use are critical global public health issues, but research on the determinants of expert-advised antibiotic prescribing in pediatric emergency departments (EDs) remains limited. This study aimed to quantify variability in expert antibiotic recommendatios for pediatric ED patients. Methods A cross-sectional survey was conducted in a Chinese pediatric hospital ED in 2020. Two days/quarter (one weekday/weekend day, avoiding infectious disease outbreaks) were selected and 1000 cases were randomly extracted for secondary analysis. Clinical data (without treatment details) were reviewed by two pediatric experts who provided retrospective antibiotic recommendations. Cases were enrolled upon their consensus. Factors influencing expert-advised antibiotic prescriptions in ED were analyzed. Results Expert consensus was achieved in 819/1000 cases. Among these, 174 (21.3%) cases were advised antibiotics by experts (57 cases not prescribed clinically), and 645 (78.7%) cases were not advised for antibiotics (53 cases prescribed clinically). Common diagnoses were upper respiratory tract infections (52.3%), gastroenteritis (18.1%), and lower respiratory tract infections (9.5%) with antibiotic advice rates 24.5%, 14.9%, and 38.5%, respectively. The median age of the antibiotic-advised group was 36 months [interquartile range (IQR): 12, 60], older than the not-advised group[12 months (IQR: 11, 36)]. Median white blood cell count…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.